journal article·2022-06-22

Multifunctional Hybrid Hydrogel System Enhanced the Therapeutic Efficacy of Treatments for Postoperative Glioma

Xiang Cao, Shengnan Li, Wenli Chen, Hongdan Lu, Lu Ye, Zhiyi Min, Shanbo Sun, Chuanhui Teng, Haoyuan Yin, Qi Zhang, Weichong He, Xiuzhen Wang, Wei Lv, Lingyan Lv, Hongliang Xin

ACS Applied Materials & Interfaces· Volume 14· Issue 24
Publisher page

Abstract

Glioma is the most lethal brain tumor with a poor prognosis, and a combination of multiple therapeutic strategies is critical for postoperative glioma treatment. Herein, a multifunctional hybrid hydrogel system (designated as CP&CL@RNPPTX-Gel) was developed for local treatment of postoperative glioma. The system was composed of self-illuminating chlorin e6 (Ce6) conjugated with luminol molecule (CL)-loaded glioma-targeting paclitaxel prodrug nanoparticles and copper peroxide nanodots (CP NDs) coembedded into a three-dimensional thermosensitive hydroxypropyl chitin hydrogel frame. After injection of CP&CL@RNPPTX-Gel into the cavity of postoperative glioma, the solution could be cross-linked into the gel as a drug reservoir under body temperature stimulation. Then, the sustained-released CP NDs decomposed into Cu2+ and H2O2 in the acidic microenvironment of the glioma cells to exert chemodynamic therapy (CDT). Meanwhile, Cu2+ could catalyze the self-luminescence of CL to induce photodynamic therapy (PDT) without external excitation light. Moreover, paclitaxel prodrug nanoparticles degraded into paclitaxel to restrain residual glioma cells in response to intracellular reduced glutathione (GSH). The in vitro and in vivo results showed that CP&CL@RNPPTX-Gel had great potential as a multifunctional hybrid hydrogel system with remarkable therapeutic effects for postoperative glioma treatment via a combination of chemotherapy, CDT, and PDT.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Advanced Nanomaterials in Catalysis · Luminescence and Fluorescent Materials

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Pharmaceutics and Key Laboratory of Cardiovascular & Cerebrovascular Medicine, School of Pharmacy, Nanjing Medical University, Nanjing 211166, China

Department of Rehabilitation Medicine, ZhongDa Hospital of Southeast University, Nanjing 210009, China

Department of Pharmacy, The Affiliated Jiangyin Hospital of Xuzhou Medical University, Wuxi 214400, China

Funding

Natural Science Foundation of Jiangsu Province · National Natural Science Foundation of China · Suzhou Science and Technology Development Plan · Outstanding Youth Foundation of Jiangsu Province · Research project on the development of the disabled in Jiangsu Province · Project of Jiangsu Health Development Research Center · Nanjing Health Science and Technology development special fund project

References (32)

Show source-provided references
1. 10.1016/S0140-6736(18)30990-510.1016/S0140-6736(18)30990-5 ↗
2. 10.1056/NEJMoa180545310.1056/NEJMoa1805453 ↗
3. 10.1016/j.canlet.2020.02.00210.1016/j.canlet.2020.02.002 ↗
4. 10.1038/s41568-021-00397-310.1038/s41568-021-00397-3 ↗
5. 10.1056/NEJMoa171643510.1056/NEJMoa1716435 ↗
6. 10.1056/NEJMoa06781910.1056/NEJMoa067819 ↗
7. 10.1016/j.wneu.2019.10.07810.1016/j.wneu.2019.10.078 ↗
8. 10.1146/annurev.med.60.052907.09493610.1146/annurev.med.60.052907.094936 ↗
9. 10.1021/jacs.9b0350310.1021/jacs.9b03503 ↗
10. 10.1038/s41467-018-05798-x10.1038/s41467-018-05798-x ↗
11. 10.1021/acsnano.6b0665110.1021/acsnano.6b06651 ↗
12. 10.1002/tcr.20160012110.1002/tcr.201600121 ↗
13. 10.1039/C7CS00594F10.1039/C7CS00594F ↗
14. 10.1126/sciadv.aat295310.1126/sciadv.aat2953 ↗
15. 10.1039/D0CS00348D10.1039/D0CS00348D ↗
16. 10.1016/j.talanta.2020.12149810.1016/j.talanta.2020.121498 ↗
17. Xu B. · Adv. Mater. · 2020 · 32 · e200356310.1002/adma.202003563 ↗
18. 10.1021/jacs.9b0345710.1021/jacs.9b03457 ↗
19. 10.1056/NEJM19950413332150710.1056/NEJM199504133321507 ↗
20. 10.1021/acsami.6b1380510.1021/acsami.6b13805 ↗
21. 10.1016/j.pharmthera.2013.05.00310.1016/j.pharmthera.2013.05.003 ↗
22. 10.1016/j.wneu.2015.03.05210.1016/j.wneu.2015.03.052 ↗
23. 10.1016/0360-3016(89)90941-310.1016/0360-3016(89)90941-3 ↗
24. 10.2147/IJN.S24898710.2147/IJN.S248987 ↗
25. 10.1016/S0169-409X(02)00054-610.1016/S0169-409X(02)00054-6 ↗
26. 10.1016/j.jconrel.2015.05.27210.1016/j.jconrel.2015.05.272 ↗
27. 10.1016/j.ijpharm.2018.07.03310.1016/j.ijpharm.2018.07.033 ↗
28. 10.1038/s41565-020-00843-710.1038/s41565-020-00843-7 ↗
29. 10.1016/j.carbpol.2018.03.03110.1016/j.carbpol.2018.03.031 ↗
30. 10.3390/s2020595210.3390/s20205952 ↗
31. 10.1021/jacs.1c0033110.1021/jacs.1c00331 ↗
32. 10.1016/j.jneumeth.2017.04.01910.1016/j.jneumeth.2017.04.019 ↗